Isolation and purification of a modified phenazine, griseoluteic acid, produced by Streptomyces griseoluteus P510

Antibiotic phenazine derivatives and their formation pathways were studied in a new Streptomyces strain P510. Culture characteristics and 16S rRNA nucleotide analysis confirmed strain P510 as Streptomyces griseoluteus. The culture medium of this strain showed strong antimicrobial and antifungal activities. Using organic solvent extraction, silica gel column chromatography and HPLC, a modified phenazine, griseoluteic acid, and a shikimic acid-derived metabolite, p-hydroxybenzaldehyde, were separated and purified. In addition, the biological activity of griseoluteic acid (GA), an important intermediate for biosynthesis of phenazine derivatives, was also investigated in this research. It significantly inhibited growth of Bacillus subtilis. The presence of GA and p-hydroxybenzaldehyde implied that the phenazine biosynthesis pathway in S. griseoluteus P510 might be initiated with shikimic acid, using phenazine-1, 6-dicarboxylic acid as the precursor. The discovery of a partial analogical sequence of phenazine biosynthetic genes, sgpC, sgpD and sgpE, in S. griseoluteus P510 further supported this hypothesis.